Malignant Peritoneal and Retroperitoneal Neoplasm

Observed

← altered in cohorts of

AVPR1A

70 / 92 cases (76 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

BAZ2A

70 / 92 cases (76 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

CAND1

70 / 92 cases (76 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

HSD17B6

70 / 92 cases (76 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

NACA

70 / 92 cases (76 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

AGAP2

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

ATP23

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

ATP5F1B

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

AVIL

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

BIN2

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

CDK4

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

CTDSP2

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

CYP27B1

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

DYRK2

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

EEF1AKMT3

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

FRS2

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

IL22

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

KMT2D

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

MARCHF9

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

METTL1

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

OS9

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

PRIM1

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

PTGES3

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

RBMS2

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

STAT6

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

TSFM

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

TSPAN31

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

ZBTB39

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

ANKRD52

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

ARHGAP9

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

ARHGEF25

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

B4GALNT1

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

BEST3

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

C12orf66

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

CELA1

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

CPM

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

CSRNP2

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

DCTN2

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

DDIT3

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

DPY19L2

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

DTX3

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

ERBB3

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

ESYT1

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

GLI1

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

GLS2

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

GNS

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

GPR182

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

GRIP1

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

HDAC7

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

HIGD1C

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

IL26

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

INHBC

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

INHBE

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

KIF5A

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

KRT74

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

KRT75

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

KRT84

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

LETMD1

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

LGR5

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

LRRC10

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

LRRC43

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

MDM2

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

METTL7A

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

MSRB3

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

MYO1A

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

NAB2

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

NDUFA4L2

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

NEMP1

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

NUP107

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

NXPH4

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

PCED1B

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

PIP4K2C

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

POU6F1

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

RAB3IP

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

RAP1B

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

RDH16

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

RPL41

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

RXYLT1

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

SCN8A

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

SHMT2

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

SLC11A2

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

SLC35E3

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

SMAGP

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

SPRYD4

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

SRGAP1

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

STAC3

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

SUOX

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

TAC3

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

TFCP2

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

XPOT

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

YEATS4

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

ZC3H10

68 / 92 cases (74 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

ZFPM1

47 / 90 cases (52 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

MUC5B

35 / 90 cases (39 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

GARS1

34 / 90 cases (38 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

ZNF517

33 / 90 cases (37 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

LRIG1

31 / 90 cases (34 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

MUC2

28 / 90 cases (31 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

LACTB

27 / 90 cases (30 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

OBSCN

27 / 90 cases (30 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

CCDC102A

26 / 90 cases (29 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

OPRD1

26 / 90 cases (29 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

SOWAHA

26 / 90 cases (29 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

TOR3A

25 / 90 cases (28 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

USP42

25 / 90 cases (28 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

CRIPAK

24 / 90 cases (27 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

PODXL

24 / 90 cases (27 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

ZNF787

24 / 90 cases (27 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

TRIOBP

23 / 90 cases (26 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

MAL2

22 / 90 cases (24 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

MUC16

22 / 90 cases (24 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

IRX3

21 / 90 cases (23 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

MUC4

21 / 90 cases (23 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

TPO

21 / 90 cases (23 %) · ssm · acc_tcga

—

Observed

← altered in cohorts of

TMEM247

20 / 90 cases (22 %) · ssm · acc_tcga

—

Observed

Malignant Peritoneal and Retroperitoneal Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 130show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 78 trials (21 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	78	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 71 trials (21 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	71	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 54 trials (21 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	54	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 33 trials (17 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	33	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 29 trials (7 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	29	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 28 trials (7 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	28	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 26 trials (7 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	26	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 24 trials (10 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 24 trials (3 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall molecule 21 trials (14 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	21	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 15 trials (5 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Niraparibsmall molecule 13 trials (5 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 10 trials (1 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Pemetrexedsmall molecule 10 trials (3 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Cabozantinibsmall molecule 8 trials (4 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	8	Observed	clinicaltrials	graph →

Malignant Peritoneal and Retroperitoneal Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 130show all (up to 200)

→ investigated in trials for

Paclitaxelsmall molecule

78 trials (21 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

71 trials (21 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

54 trials (21 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

33 trials (17 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cisplatinsmall molecule

29 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall molecule

28 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

26 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gemcitabinesmall molecule

24 trials (10 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Topotecansmall molecule

24 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Olaparibsmall molecule

21 trials (14 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

15 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Niraparibsmall molecule

13 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Docetaxelsmall molecule

10 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pemetrexedsmall molecule

10 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cabozantinibsmall molecule

8 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

Primary Peritoneal Carcinoma

Malignant Peritoneal and Retroperitoneal Neoplasm studied in …STUDIED_INderived10 of 631show all (up to 200)
→ studied in	NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 631 trials mapped (189 active)	—	—	Primary Peritoneal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 631 trials mapped (189 active)	—	—	Primary Peritoneal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 631 trials mapped (189 active)	—	—	Primary Peritoneal Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · condition mapped CURATED_BROADER · 631 trials mapped (189 active)	—	—	Primary Peritoneal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06487481Phase 1 · recruiting Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma · condition mapped ALIAS · 631 trials mapped (189 active)	—	—	Adrenal Cortical Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 631 trials mapped (189 active)	—	—	Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07715903Phase 1 · not yet recruiting Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy · condition mapped ALIAS · 631 trials mapped (189 active)	—	—	Adrenal Cortical Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06057935Phase 2 · recruiting A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma · condition mapped ALIAS · 631 trials mapped (189 active)	—	—	Peritoneal Malignant Mesothelioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07776691Phase 3 · recruiting A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) · condition mapped ALIAS · 631 trials mapped (189 active)	—	—	Malignant Peritoneal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07708753Phase 3 · recruiting A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers · condition mapped ALIAS · 631 trials mapped (189 active)	—	—	Platinum-Resistant Primary Peritoneal Carcinoma	1	Observed	clinicaltrials	graph →

Malignant Peritoneal and Retroperitoneal Neoplasm studied in …STUDIED_INderived10 of 631show all (up to 200)

→ studied in

NCT02345265Phase 2 · active not recruiting

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 631 trials mapped (189 active)

—

Observed

Primary Peritoneal Carcinoma

→ studied in

NCT02446600Phase 3 · active not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 631 trials mapped (189 active)

—

Observed

Primary Peritoneal Serous Adenocarcinoma

→ studied in

NCT02502266Phase 2/Phase 3 · active not recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 631 trials mapped (189 active)

—

Observed

Primary Peritoneal Carcinoma

→ studied in

NCT05564377Phase 2 · recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · condition mapped CURATED_BROADER · 631 trials mapped (189 active)

—

Observed

→ studied in

NCT06487481Phase 1 · recruiting

Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma · condition mapped ALIAS · 631 trials mapped (189 active)

—

Observed

Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma

→ studied in

NCT07504588Phase 2 · recruiting

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 631 trials mapped (189 active)

—

Observed

→ studied in

NCT07715903Phase 1 · not yet recruiting

Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy · condition mapped ALIAS · 631 trials mapped (189 active)

—

Observed

Peritoneal Malignant Mesothelioma

→ studied in

NCT06057935Phase 2 · recruiting

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma · condition mapped ALIAS · 631 trials mapped (189 active)

—

Observed

Malignant Peritoneal Neoplasm

→ studied in

NCT07776691Phase 3 · recruiting

A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) · condition mapped ALIAS · 631 trials mapped (189 active)

—

Observed

Platinum-Resistant Primary Peritoneal Carcinoma

→ studied in

NCT07708753Phase 3 · recruiting

A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers · condition mapped ALIAS · 631 trials mapped (189 active)

—

Observed